Hepion Pharmaceuticals, Inc. (CTRVP) Return on equity 2020–2023
Hepion Pharmaceuticals, Inc. (CTRVP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-672.0%FY2023 · since FY2020: -50.2% → -672.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -672.0% | -587.3 pp |
| FY2022 | -84.6% | -49.5 pp |
| FY2021 | -35.2% | +15.0 pp |
| FY2020 | -50.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CTRVP financial trends
CTRVP RevenueCTRVP Net incomeCTRVP Net marginCTRVP Gross profitCTRVP Gross marginCTRVP Operating incomeCTRVP Operating marginCTRVP Operating cash flowCTRVP Free cash flowCTRVP Capital expendituresCTRVP Stock buybacksCTRVP Dividends paidCTRVP Total assetsCTRVP Total liabilitiesCTRVP Shareholders’ equityCTRVP overview →